Status:
COMPLETED
Effect of Oral Glutamine on Muscle Mass and Function in Duchenne Muscular Dystrophy
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Conditions:
Muscular Dystrophy, Duchenne
Eligibility:
MALE
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine whether long-term oral glutamine supplementation is effective in improving muscle mass and function in children with Duchenne muscular dystrophy (DMD).
Detailed Description
Glutamine inhibits whole body protein degradation in children with Duchenne Muscular Dystrophy (DMD). The effect is observed after 5 h oral glutamine administration and is also found when glutamine is...
Eligibility Criteria
Inclusion
- Clinical diagnosis of Duchenne muscular dystrophy
- Able to walk \>170 m
- Absence of hepatic insufficiency
- Absence of renal insufficiency
Exclusion
- Dependent upon wheelchair
- Body weight \>60kg
- Liver failure
- Kidney failure
- Surgery scheduled during the year following the first visit
Key Trial Info
Start Date :
February 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2007
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00296621
Start Date
February 1 2006
End Date
November 1 2007
Last Update
December 21 2007
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre d'Investigation Clinique, Hôpital Cardiologique, CHR&U de Lille
Lille, France, 59037
2
Service d'Hépato Gastro Entérologie, Hôpital Jeanne de Flandre, CHR&U de Lille
Lille, France, 59037
3
Service de Neuropédiatrie, Hôpital Roger Salengro, CHR&U de Lille
Lille, France, 59037
4
Centre d'Investigation Clinique (CIC9202), Hôpital Robert Debré, Assistance Publique-Hôpitaux de Paris
Paris, France, 75935